Validity of self-report of infections in a longitudinal cohort of patients with rheumatoid arthritis differs by source of report and infection severity

Journal of Clinical Epidemiology

Volumn 63, Issue 12, 2010, Pages 1358-1362

  Simard, Julia F ^a   Stoll, Matthew L ^b,c   Shadick, Nancy A ^d   Karlson, Elizabeth W ^d   Solomon, Daniel H ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Infection validation; Medical record review; Pharmacoepidemiology; Rheumatoid arthritis; Self report; Validation study

Indexed keywords

ANTIBIOTIC AGENT;

ARTICLE; BRONCHITIS; CELLULITIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEALTH CARE PERSONNEL; HUMAN; INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OPPORTUNISTIC INFECTION; OSTEOMYELITIS; PHARMACOEPIDEMIOLOGY; PNEUMONIA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SELF REPORT; SEPSIS; VALIDATION STUDY;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DIAGNOSTIC SELF EVALUATION; DISABILITY EVALUATION; FEMALE; HUMANS; INFECTION; LONGITUDINAL STUDIES; MEDICAL RECORDS; PAIN MEASUREMENT; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RHEUMATOLOGY; SELF REPORT; UNITED STATES;

EID: 78049307472     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2010.01.014     Document Type: Article

References (8)

1. A. Breckenridge Post-marketing strategies for medicines Clin Pharmacol Ther 83 2008 24 25 discussion 25
2. S. Schneeweiss, A. Robicsek, R. Scranton, D. Zuckerman, and D.H. Solomon Veteran's affairs hospital discharge databases coded serious bacterial infections accurately J Clin Epidemiol 60 2007 397 409
3. M.J. van der Veen, A. van der Heide, A.A. Kruize, and J.W. Bijlsma Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate Ann Rheum Dis 53 1994 224 228
4. A.M. Boerbooms, P.J. Kerstens, J.W. van Loenhout, J. Mulder, and L.B. van de Putte Infections during low-dose methotrexate treatment in rheumatoid arthritis Semin Arthritis Rheum 24 1995 411 421
5. J. Askling, C.M. Fored, L. Brandt, E. Baecklund, L. Bertilsson, and N. Feltelius Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists Ann Rheum Dis 66 2007 1339 1344
6. T. Bongartz, A.J. Sutton, M.J. Sweeting, I. Buchan, E.L. Matteson, and V. Montori Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 2006 2275 2285
7. W.G. Dixon, K. Watson, M. Lunt, K.L. Hyrich, A.J. Silman, and D.P. Symmons Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register Arthritis Rheum 54 2006 2368 2376
8. J.R. Curtis, C. Martin, K.G. Saag, N.M. Patkar, J. Kramer, and D. Shatin Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs Arthritis Rheum 57 2007 343 346